Botox and exosomes together on one appointment is a sequencing question, and the published record answers it only in part. No located human study has paired botulinum toxin type A with topical exosome material, so what a practice can read comes from studies that paired the neurotoxin with lasers, light, ultrasound and microneedling, plus the drug label and the FDA position on exosome products [1, 2, 3, 17].
Those studies ran both orders. Some applied a light or laser device within minutes after the neurotoxin, some placed the device first and the neurotoxin after, and some separated a needling or ultrasound session from the neurotoxin by one to two weeks [3, 4, 6, 19]. This guide sets out what each study did and found, why microneedling over a fresh toxin area draws more caution than surface light, and what to record when both steps share a day.
Botox and Botox Cosmetic are registered trademarks of their owner, and the product is named here only to identify it.
Regulatory position
Botox Cosmetic is an FDA-approved biologic under BLA 103000, given by intramuscular injection for the indications on its label [1]. The FDA stated in its 2019 public safety notification, still posted on fda.gov as of 9 November 2026, that there are currently no FDA-approved exosome products [17]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats. Sequence, timing and patient selection are practitioner decisions this article does not make.
Exosomes vs Botox: two products in different regulatory categories
The Botox Cosmetic label states that onabotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent indicated in adults for the temporary improvement in the appearance of moderate to severe glabellar, lateral canthal and forehead lines and platysma bands [1]. The label also states that its units cannot be compared to or converted into units of any other botulinum toxin product, which matters when a study used a different brand [1].
The label carries a boxed warning on distant spread of toxin effect. It reports that postmarketing cases describe effects beyond the injection site, appearing hours to weeks after injection [1]. Section 5.2 of the label also states that no definitive serious adverse event reports of distant spread associated with its dermatologic uses at the labeled doses have been reported [1].
Exosome material sits in a different place. The FDA stated in 2019 that there are no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products [17]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats, and its labeling describes the manufacturing conditions, the FDA registration of the manufacturing site and cGMP manufacture, so on a combined day the two products arrive under different rules, by different routes and with different paperwork.
| Feature | Botulinum toxin type A (Botox Cosmetic) | Exosome material |
|---|---|---|
| FDA status | Approved biologic, BLA 103000 [1] | No FDA-approved exosome product, per the 2019 FDA notification [17] |
| What the labeling describes | Indications, intramuscular injection and dosing [1] | For ExaVeyra material: the manufacturing conditions, the FDA registration of the manufacturing site and cGMP manufacture |
| Route in the published studies | Intramuscular injection [1] | Surface application by a licensed practitioner in the published topical studies |
| Where it acts | Acetylcholine release at the neuromuscular junction [1] | Applied to the skin surface |
| Key safety language | Boxed warning on distant spread of toxin effect [1] | FDA notification directing adverse event reports to MedWatch [17] |
| Documentation | Prescribing information, Medication Guide, lot and expiry | Lot number on the vial; certificate of analysis, characterization panel and cold-chain records for the lot on request |
Published sequencing studies paired the neurotoxin with devices
Semchyshyn and Kilmer tested the device-after-toxin order in 2005. Nineteen adults received toxin to the glabella or crow’s feet, one side was then exposed within ten minutes to a pulsed dye laser, a 1450 nm diode laser, a 1064 nm Nd:YAG laser, intense pulsed light or a radiofrequency device, and two-week photographs showed no loss of toxin effect on the exposed side [19].
Pomerantz and colleagues reviewed 616 same-day sessions in 393 people from 2017 to 2019, each pairing glabellar or periorbital toxin with full-face non-ablative fractional laser at 1927 or 1550 nm. They documented eyelid ptosis once, a rate of 0.2 percent, and concluded that the risk of spread to an unintended muscle was minimal in that setting [2].
Carruthers and Carruthers randomized 30 women in 2004 to broadband light with toxin or broadband light alone and reported a better response in the combination group, though the abstract does not state the order within a visit [20]. In a 2026 case series of five patients, Rodrigo Crisanto de Oliveira ran a carbon-assisted Q-switched laser first, the neurotoxin immediately after and a topical step last, and reported the toxin effect clinically preserved through follow-up of up to six months [10].
Two reviews gather this work. Cuerda-Galindo and colleagues examined 15 studies in 2015, eight of them pairing a device with toxin, and reported no rise in adverse effects and no loss of efficacy with same-day combinations, noting that practices usually ran lasers first out of concern that light could degrade the injected product [11]. Fritz and colleagues reviewed the same-day literature in 2026 and reported that the studies consistently found no reduction in toxin efficacy with close timing, with fractional RF microneedling and high-intensity focused ultrasound as the stated exceptions [5].
| Study | Order studied | Design and n | What was reported |
|---|---|---|---|
| Semchyshyn 2005 [19] | Toxin, then laser, IPL or RF within 10 minutes | Within-subject comparison, 19 | No loss of toxin effect at 2 weeks |
| Pomerantz 2021 [2] | Toxin and full-face non-ablative fractional laser, same day | Retrospective review, 616 sessions in 393 people | Eyelid ptosis in 1 session (0.2%) |
| Harnchoowong 2025 [3] | Toxin, then micro-focused ultrasound same day, day 7 or day 14 | Randomized within-subject, 15 | Smaller intradermal toxin effect at every ultrasound site, with the largest reduction on the same day |
| Li 2026 [4] | RF microneedling, then toxin 1 week later | Retrospective cohort, 35 | No significant wrinkle-score difference between groups after adjustment; elasticity and hydration favored the combination |
| Rodrigo Crisanto de Oliveira 2026 [10] | Q-switched laser, then toxin, then topical step | Case series, 5 | Toxin effect clinically preserved |
| Carruthers 2004 [20] | Broadband light with toxin, order not stated | Randomized, 30 | Better response with the combination |
Understanding why some practices wait before microneedling over a fresh toxin area
No located study has tested microneedling, with or without exosome material, directly over an area that received toxin the same day. The caution some practices describe rests on adjacent evidence, and it helps to see each piece separately.
The first piece is the label’s boxed warning on spread beyond the injection site [1]. The second is that microneedle channels can carry toxin into skin: Iraji and colleagues randomized 30 patients in 2025 to intradermal toxin on one side of the face and toxin applied after microneedling on the other, and reported no significant difference in pore outcomes at one month, which is consistent with toxin on needled skin reaching the dermis [8].
The third piece is mechanical and thermal energy delivered after toxin. Harnchoowong and colleagues randomized four forehead sites in each of 15 adults in 2025 and reported smaller anhidrotic areas at every site that received micro-focused ultrasound, 0.74 square centimeters on the same day, 0.90 at day 7 and 0.93 at day 14, against 1.10 at untouched sites [3]. The authors advised avoiding that device for at least two weeks after toxin, and their endpoint measured intradermal toxin by a sweat test [3].
The located study that paired RF microneedling with toxin placed the needling first. Li and colleagues reported in 2026 on 15 patients who had one RF microneedling session followed by toxin a week later, compared with 20 who had toxin alone [4], and Fritz and colleagues named fractional RF microneedling as an exception to the same-day pattern in their 2026 review [5].
Movement and warmth after injection have also been modeled. Rahman and colleagues simulated 10,000 paired virtual patients in 2026 and reported median changes in spread radius at four hours of 0.08 to 0.14 millimeters for bending, exercise, rubbing or mild heat alone and 0.22 millimeters with all combined, with most variation driven by tissue and injection factors such as diffusivity and injection depth [9]. Several authors declared ties to toxin manufacturers, and the authors stated that clinical trials are still required [9].
Reading channel timing alongside toxin timing
Gupta and colleagues reported in 2011 that unoccluded microneedle sites recovered barrier function within about two hours, while occluded sites stayed permeable for 3 to 40 hours [12]. That timing describes the skin barrier, while the toxin studies above describe the toxin’s effect. A practice weighing the two is matching the device session to the neurotoxin, and the topical step follows whichever order the practitioner chooses.
Same appointment or staggered: consensus and surveys describe both
A panel of 15 specialists led by Carruthers published consensus recommendations in 2016 for combining toxin, fillers and micro-focused ultrasound on the face. The panel described spacing consecutive sessions one to two weeks apart to let side effects resolve and results be assessed, performing toxin and filler on the same day in either order, and running micro-focused ultrasound before injectables [6].
Practice surveys show the same range. Dempsey and colleagues sent a survey to 65 leading laser dermatologists in 2023, received 37 responses, and reported that most respondents were comfortable combining same-day device sessions with toxin, specifically vascular and Q-switched or picosecond lasers, while noting that variations exist even at expert level [7].
For a topical exosome step, the published orders give a practitioner a frame rather than a rule. Where a session pairs neurotoxin with a light-based device, the studies above ran the device both before and after [10, 19]. Where it pairs neurotoxin with needling or focused ultrasound, the located cohort and the consensus placed the device first, and the randomized ultrasound study reported a smaller toxin effect at every site that received the device after toxin, through day 14 [3, 4, 6]. Surface application of exosome material is described in the exosome studies alongside the needling session [13, 14].
Microneedling with exosomes and Botox draws on separate bodies of evidence
The exosome side of a combined day comes from microneedling and device trials without toxin. Park and colleagues ran a randomized split-face study of 28 participants in 2023, applying an adipose stem cell exosome solution to one side and saline to the other with three microneedling sessions, and reported higher aesthetic improvement scores and instrument-measured gains in wrinkles, elasticity, hydration and pigmentation on the exosome side, with no serious adverse events observed [13].
Gaebe and colleagues reviewed 16 facial vesicle studies with 503 participants in 2026. They reported that most found improvement in at least one skin-quality outcome and that no serious adverse events were reported, and they rated risk of bias as moderate to critical for most effectiveness outcomes and certainty of evidence as low or very low [14]. The review’s abstract describes no toxin combination [14].
The two located papers that combine exosomes with botulinum toxin are both preclinical. Wang and colleagues reported in 2025 on exosomes engineered to carry the toxin receptor SV2C and complexed with toxin, studied in fibroblasts and by intradermal injection in mice [15], and Zheng and colleagues reported in 2024 on rat adipose stem cell exosomes given with toxin in fibroblast cultures and a rat skin wound model [16]. Both sit far from a licensed neurotoxin and a separate topical step in a practice.
The FDA’s microneedling page adds a regulatory note to any combined protocol. It states that microneedling devices are not approved for delivery of cosmetics, topical medications, drugs or blood products into the skin, and that the risks of combining the devices with other products are not known [18].
Understanding what the evidence does not yet show
The sequencing literature is practical and growing, and its gaps are specific enough to list. Each one points to a study a practice or investigator could design.
- No located human study has paired botulinum toxin with topical exosome material, in either order or on separate days; the two located combination papers are preclinical [15, 16].
- No located study has tested microneedling directly over a same-day toxin area; the caution rests on the label, on microneedling-assisted toxin studies such as Iraji 2025, and on the ultrasound timing data of Harnchoowong 2025 [1, 3, 8].
- Samples are small outside Pomerantz 2021, which was retrospective and identified ptosis from follow-up documentation or an apraclonidine prescription [2].
- Toxin brands differ across studies, and the Botox Cosmetic label states that its units cannot be compared to or converted into units of other toxin products [1, 10].
- Endpoints vary from photographs and wrinkle scales to a sweat test of intradermal toxin, so results do not transfer cleanly to muscle activity [3, 4, 19].
- Rahman 2026 modeled post-injection spread in simulated patients, and its authors called for clinical trials and declared toxin manufacturer ties [9].
- Gaebe 2026 rated the certainty of facial vesicle evidence as low or very low, and exosome materials differ by source, isolation and concentration [14].
What to ask and document when toxin and topical steps share a day
A practice that records the same fields the published studies report can compare its own experience with the literature and answer questions from one file. The fields below follow the studies and labeling cited above [1, 2, 3, 13].
- The neurotoxin by brand, lot and expiry, the injection sites, and the time of injection
- Any device by model and FDA clearance, with mode, energy, needle depth and the time of the session relative to the neurotoxin
- The order of steps in the appointment, and the reason for that order in the practitioner’s notes
- The exosome material by name and class, with its lot number, certificate of analysis, characterization panel and cold-chain record from receipt to use
- The time between thawing or preparing the exosome material and surface application
- Follow-up observations at the points the studies used, such as two weeks for the neurotoxin effect
- Any adverse event, with both lot numbers, reported to the FDA through MedWatch [17]
Patients reading this can take the same list to a consultation and ask their provider which order they use and why. The answer belongs to the treating practitioner, and the studies above show that thoughtful practices have reached it in more than one way.
Combined appointments are becoming a normal part of aesthetic practice, and the evidence base is set to grow as practices document their sequences carefully. ExaVeyra supplies exosome material to licensed practitioners; it ships frozen from the manufacturing facility with the lot number on every vial, and the certificate of analysis generated for each lot is available on request with its characterization panel and cold-chain records, so the topical step in any protocol can be documented as fully as the neurotoxin beside it. Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice planning combined days can start with a question or an application today.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
References
- 1.U.S. Food and Drug Administration. BOTOX Cosmetic (onabotulinumtoxinA) for injection, prescribing information and Medication Guide, BLA 103000, revised 10/2024 (supplements 5316, 5319, 5323, 5326, 5331, approved October 18, 2024). Verified against the current DailyMed SPL (version 54, published January 8, 2026) on 9 November 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5316s5319s5323s5326s5331lbl.pdfFDA-approved labeling for the biologic (Drugs@FDA; the same label is on DailyMed under set id 485d9b71-6881-42c5-a620-a4360c7192ab). Carries in this article: the four approved aesthetic indications in adults, intramuscular administration, the boxed warning on distant spread of toxin effect reported hours to weeks after injection, the statement in section 5.2 that no definitive serious adverse event reports of distant spread associated with dermatologic use at the labeled doses have been reported, and the statement that units cannot be compared to or converted into units of any other botulinum toxin product.
- 2.Pomerantz H, Akintilo L, Shaw K, Lederhandler M, Anolik R, Geronemus RG. Safety Profile of Combined Same-Day Treatment for Botulinum Toxin With Full Face Nonablative Fractionated Laser Resurfacing. Dermatol Surg. 2021;47(4):500-503. PMID 33165055. doi:10.1097/DSS.0000000000002851Single-center retrospective chart review (New York), 2017 to 2019; 616 same-day sessions in 393 people pairing glabellar or periorbital toxin with full-face non-ablative fractional laser (1927 nm thulium or 1550 nm erbium glass). Carries in this article: the largest located same-day dataset; eyelid ptosis was documented once (0.2 percent), and the authors concluded the risk of spread to an unintended muscle was minimal in that setting. Disclosure: no COI statement in the PubMed record.
- 3.Harnchoowong S, Jurairattanaporn N, Vachiramon V. The Effect of Micro-Focused Ultrasound Treatment on Intradermal Botulinum Toxin Type A Injection. Toxins (Basel). 2025;17(3):147. PMID 40137920. PMC11945533. doi:10.3390/toxins17030147Randomized within-subject controlled study (Thailand); 15 adults, four intradermal forehead toxin sites each, randomized to no micro-focused ultrasound or ultrasound on the same day, day 7 or day 14. Carries in this article: the only located randomized timing study; anhidrotic area at day 28 was 1.10 cm2 at control sites against 0.74, 0.90 and 0.93 cm2 at the same-day, day 7 and day 14 sites, and the authors advised avoiding the device for at least two weeks after toxin. The endpoint is a sweat test of intradermal toxin, not muscle activity. Disclosure: the authors declared no conflicts of interest.
- 4.Li Y, Chen X, Ge L. Efficacy and Safety of Microneedle Fractional Radiofrequency Combined with Botulinum Toxin Type A for Periorbital Aging: A Retrospective Cohort Study. Clin Cosmet Investig Dermatol. 2026;19:620438. PMID 42827935. PMC13632624. doi:10.2147/CCID.S620438Retrospective cohort (China), 2022 to 2025; 35 patients, 20 receiving toxin alone and 15 receiving one RF microneedling session followed by toxin one week later, followed for 24 weeks. Carries in this article: a published staggered sequence with the device first; no between-group wrinkle-score difference survived multiplicity adjustment, while elasticity and hydration changes favored the combination and water loss rose transiently at week 2. Disclosure: the authors reported no conflicts of interest.
- 5.Fritz K, Salavastru C, Eren S, Tiplica GS. [Botulinumtoxin A in simultaneous combination with lasers and energy-based devices (EBD)]. Dermatologie (Heidelb). 2026;77(3):169-175. PMID 41543534. doi:10.1007/s00105-025-05637-3Narrative literature review in German (Germany and Romania) of studies applying lasers and energy-based devices on the same day as toxin. Carries in this article: the reviewed studies consistently reported no loss of toxin efficacy with close timing, with the stated exceptions of fractional RF microneedling and high-intensity focused ultrasound. Disclosure: the authors declared no conflicts of interest.
- 6.Carruthers J, Burgess C, Day D, Fabi SG, Goldie K, Kerscher M, et al. Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg. 2016;42(5):586-97. PMID 27100962. doi:10.1097/DSS.0000000000000754Expert consensus of 15 specialists from North America, Europe and Korea under a moderator; consensus defined as 75 to 94 percent agreement, strong consensus at 95 percent or more. Carries in this article: the panel described spacing consecutive sessions 1 to 2 weeks apart, same-day toxin and filler in either order, and micro-focused ultrasound before injectables. Disclosure: funding and disclosures are not stated in the PubMed record; check the full text.
- 7.Dempsey A, Watchmaker J, Hibler BP, Rossi A. Practice patterns regarding combination treatments and laser and energy based devices: A survey of American Society for Laser Medicine and Surgery Members. Lasers Surg Med. 2023;55(1):16-21. PMID 36655516. doi:10.1002/lsm.23632Anonymous survey of leading ASLMS dermatologists; 37 of 65 responded. Carries in this article: most respondents reported comfort combining same-day laser or device sessions with toxin, specifically vascular and Q-switched or picosecond lasers, and the authors noted wide variation even at expert level. Disclosure: no COI statement in the PubMed record.
- 8.Iraji F, Moeini R, Abedini M, Mousavi MS, Saber M, Barghani MRR, et al. Comparison of Intradermal Versus Microneedling-Assisted Botulinum A Toxin Injection for Enlarged Facial Pores: A Randomized Clinical Trial. J Cosmet Dermatol. 2025;24(6):e70114. PMID 40522143. PMC12169069. doi:10.1111/jocd.70114Randomized split-face trial (Iran); 30 adults, intradermal toxin on one side and microneedling-assisted toxin on the other, assessed by three blinded dermatologists at one month. Carries in this article: toxin moved into skin through microneedle channels produced an effect comparable to intradermal placement, the published basis for reading microneedle channels as a route for toxin. Disclosure: the authors declared no conflicts of interest.
- 9.Rahman E, Michon A, Rao P, Ahmed M, Joseph JH, Wu WT, et al. Breaking the 4-hour rule: Multiscale computational modelling redefines post-injection restrictions for botulinum neurotoxin A. Toxicon. 2026;271:108950. PMID 41407077. doi:10.1016/j.toxicon.2025.108950Computational modelling study; 10,000 paired simulated patients comparing rest with bending, light exercise, superficial rubbing, mild heat and a combined scenario in the first four hours. Carries in this article: modelled changes in spread radius were small (medians 0.08 to 0.22 mm), driven mainly by injection depth and tissue factors, and the authors stated that clinical trials are still required. Disclosure: several authors declared consulting, speaking, advisory or investigator ties to botulinum toxin manufacturers, and one author founded the modelling platform, as declared in the record.
- 10.Rodrigo Crisanto de Oliveira R. One-day rejuvenation: a preliminary case series of a multimodal protocol combining Q-switched 1064 nm laser, botulinum toxin, and laser-assisted delivery of PDRN and retinoids. J Cosmet Laser Ther. 2026:1-4. Published online ahead of print. PMID 42418230. doi:10.1080/14764172.2026.2698113Pilot case series (Brazil); 5 patients. Carries in this article: a published single-session order of carbon-assisted Q-switched laser first, intramuscular incobotulinumtoxinA immediately after, then topical polydeoxyribonucleotide and retinoic acid; the author reported toxin effect clinically preserved through follow-up of up to six months. Disclosure: single author; no COI statement in the PubMed record.
- 11.Cuerda-Galindo E, Palomar-Gallego MA, Linares-Garcíavaldecasas R. Are combined same-day treatments the future for photorejuvenation? Review of the literature on combined treatments with lasers, intense pulsed light, radiofrequency, botulinum toxin, and fillers for rejuvenation. J Cosmet Laser Ther. 2015;17(1):49-54. PMID 25260050. doi:10.3109/14764172.2014.968578Literature review (Spain) of 15 studies, 3 in animals and 12 clinical, eight of them pairing a light or energy device with toxin. Carries in this article: the reviewed studies reported no increase in adverse effects and no loss of efficacy of the injected product with same-day combinations, and the authors noted that practices usually ran lasers before injectables out of concern that energy could degrade the product. Disclosure: no COI statement in the PubMed record.
- 12.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human in vivo study using electrical impedance spectroscopy across microneedle geometries, with and without occlusion. Carries in this article: unoccluded microneedle sites recovered barrier properties within about two hours, while occluded sites stayed permeable for 3 to 40 hours depending on needle length, number and cross-section. Disclosure: academic authors (Georgia Institute of Technology); no COI statement in the PubMed record.
- 13.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study over 12 weeks, three sessions three weeks apart, saline control side (Korea); n = 28. Carries in this article: the controlled template for exosome material applied with microneedling, with instrument endpoints for wrinkles, elasticity, hydration and pigmentation and no serious adverse events observed; toxin was not part of the protocol. Disclosure: National Research Foundation of Korea grants listed in the PubMed record; no COI statement in the record.
- 14.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: most studies reported improvement in at least one skin-quality outcome and no serious adverse events, risk of bias was moderate to critical for most effectiveness outcomes, and GRADE certainty was low or very low; the abstract describes no toxin combination. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 15.Wang Y, Wang K, Ben X, Tian M, Liu X, Li Z, et al. Engineered Exosomes Complexed with Botulinum Toxin Type A for Enhanced Anti-Aging Effects on Skin. Biology (Basel). 2025;14(8):1040. PMID 40906387. PMC12383945. doi:10.3390/biology14081040Preclinical laboratory and mouse study (China) of exosomes from genetically modified adipose stem cells engineered to carry the toxin receptor SV2C and complexed with toxin. Carries in this article: one of two located studies combining exosomes and botulinum toxin in skin, both preclinical; it concerns an engineered complex given by intradermal injection in mice and tested in fibroblasts, far from a topical step beside a licensed toxin. Disclosure: the authors declared no conflicts of interest.
- 16.Zheng HH, Ben XY, Wang YR, Tian MS, Meng QW, Li DX, et al. Experimental study on the effect and mechanism of adipose stem cell-derived exosomes combined with botulinum toxin A on skin trauma in rats. J Cosmet Dermatol. 2024;23(1):271-283. PMID 37464738. doi:10.1111/jocd.15922Preclinical cell culture and rat study (China) of rat adipose stem cell exosomes and toxin, alone and combined, on human skin fibroblasts and a rat skin wound model. Carries in this article: the second located paper combining exosomes and botulinum toxin, again outside human skin and outside any aesthetic protocol; the authors reported faster fibroblast migration and rat wound closure with exosomes, toxin or both, and described the combination as synergistic. Disclosure: no COI statement in the PubMed record.
- 17.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, subject to premarket review; the notice also points practitioners to MedWatch for adverse event reports.
- 18.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesAgency device information page (CDRH). Carries in this article: the page states that microneedling devices are not approved for delivery of cosmetics, topical medications, drugs or blood products into the skin, and that the risks of combining the devices with other products are not known.
- 19.Semchyshyn NL, Kilmer SL. Does laser inactivate botulinum toxin? Dermatol Surg. 2005;31(4):399-404. PMID 15871314. doi:10.1111/j.1524-4725.2005.31105Prospective within-subject comparison (USA); 19 adults received toxin to the glabella or crow’s feet, then one side was exposed within 10 minutes to a pulsed dye laser, a 1450 nm diode laser, a 1064 nm Nd:YAG laser, IPL or an RF device. Carries in this article: no decrease in toxin effect was observed on photographs at two weeks, the earliest located test of a device run after toxin. Disclosure: no COI statement in the PubMed record.
- 20.Carruthers J, Carruthers A. The effect of full-face broadband light treatments alone and in combination with bilateral crow’s feet Botulinum toxin type A chemodenervation. Dermatol Surg. 2004;30(3):355-66. PMID 15008861. doi:10.1111/j.1524-4725.2004.30101.xProspective randomized study (Canada); 30 women, broadband light plus toxin against broadband light alone, with biopsies in four. Carries in this article: an early controlled comparison in which the combination group reported a better response at rest and on smiling; the abstract does not state the order of steps within a visit. Disclosure: no COI statement in the PubMed record.